

Press Release

Disclaimer This press release appears as a matter of record only and shall not constitute an offer, solicitation or recommendation in relation to any securities, investment products or investment services in any jurisdiction where it is unlawful to do so.

Nextech Invest Announces First Closing of Oncology Fund IV

Zurich (Switzerland), October 14, 2014 – Nextech Invest Ltd., the Swiss specialist cancer venture capital investor, today announced the first closing of its new global Oncology IV fund at US\$ 40 million. The Oncology IV fund is targeting a final close of US\$ 100 million. Continuing the strategy of its two predecessor oncology funds, Nextech aims to invest in cancer companies that develop transformative therapeutics or technologies. Nextech has now raised more than US\$ 220 million since its inception across four funds, of which the latter three funds are focused exclusively on oncology.

“We are pleased to see strong support and interest from both existing and new investors to build on our track record and global strategy to invest in leading oncology companies“, said Alfred Scheidegger, Founding Partner at Nextech Invest. “Through this fourth fund, Nextech Invest aims to invest in 8 – 10 cancer companies over the next three years.”

Nextech Invest is supported by an outstanding Scientific Advisory Board of seven world-leading oncologists chaired by Professor David Livingston, Dana-Farber/Harvard Cancer Center. “We are very pleased that all seven members have committed to continue working with us to select the top 1% of oncology investment opportunities throughout the world,” said Thilo Schroeder, Partner at Nextech Invest.

Currently, Nextech Invest holds eight companies in its portfolio all focusing on different cancer treatment approaches. The portfolio includes: kinase inhibitor company Blueprint Medicines; ImaginAb, the antibody fragment-based diagnostics imaging company; immunotherapy company MacroGenics; MolecularMD, a molecular diagnostics company; Palyon Medical, a developer of implantable drug pumps for palliative care; solid and hematologic cancer company Sunesis; Smac mimetics specialist Tetralogic; plus, targeted therapy company TRACON Pharmaceuticals. Over the last six years Nextech Invest has made three trade sale exits, three partial exits and two IPOs.

About Nextech Invest Ltd.

The global oncology specialist venture capital firm Nextech Invest Ltd., established in 1998 in Zurich, Switzerland, focuses on investing in cancer companies. Supported by a Scientific Advisory Board of seven oncologists chaired by Prof. Dr. David Livingston, Deputy Director Dana-Farber/Harvard Cancer Center, Nextech Invest is investing in emerging companies with pioneering innovations in cancer research that have compounds entering clinical trials. The other members of the Scientific Advisory Board are: Prof. Dr. Karl-Heinz Altmann, Prof. Dr. Glenn Dranoff, Prof. Dr. William Kaelin, Prof. Dr. Sir Bruce Ponder, Dr. Charles Sawyers and Prof. Dr. Paul Workman. Nextech Invest is a longstanding member of leading networks in private equity, such as EVCA, SECA and EVPA. Nextech Invest works closely with the Union for International Cancer Control (UICC).

For more information, please contact:

Raimund Gabriel

MC Services AG

Tel.: +49-89-210228-30

raimund.gabriel@mc-services.eu